Unknown

Dataset Information

0

Neonatal umbilical cord blood transplantation halts skeletal disease progression in the murine model of MPS-I.


ABSTRACT: Umbilical cord blood (UCB) is a promising source of stem cells to use in early haematopoietic stem cell transplantation (HSCT) approaches for several genetic diseases that can be diagnosed at birth. Mucopolysaccharidosis type I (MPS-I) is a progressive multi-system disorder caused by deficiency of lysosomal enzyme ?-L-iduronidase, and patients treated with allogeneic HSCT at the onset have improved outcome, suggesting to administer such therapy as early as possible. Given that the best characterized MPS-I murine model is an immunocompetent mouse, we here developed a transplantation system based on murine UCB. With the final aim of testing the therapeutic efficacy of UCB in MPS-I mice transplanted at birth, we first defined the features of murine UCB cells and demonstrated that they are capable of multi-lineage haematopoietic repopulation of myeloablated adult mice similarly to bone marrow cells. We then assessed the effectiveness of murine UCB cells transplantation in busulfan-conditioned newborn MPS-I mice. Twenty weeks after treatment, iduronidase activity was increased in visceral organs of MPS-I animals, glycosaminoglycans storage was reduced, and skeletal phenotype was ameliorated. This study explores a potential therapy for MPS-I at a very early stage in life and represents a novel model to test UCB-based transplantation approaches for various diseases.

SUBMITTER: Azario I 

PROVIDER: S-EPMC5573317 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications


Umbilical cord blood (UCB) is a promising source of stem cells to use in early haematopoietic stem cell transplantation (HSCT) approaches for several genetic diseases that can be diagnosed at birth. Mucopolysaccharidosis type I (MPS-I) is a progressive multi-system disorder caused by deficiency of lysosomal enzyme α-L-iduronidase, and patients treated with allogeneic HSCT at the onset have improved outcome, suggesting to administer such therapy as early as possible. Given that the best character  ...[more]

Similar Datasets

| S-EPMC5580430 | biostudies-literature
| S-EPMC8560197 | biostudies-literature
| S-EPMC5442719 | biostudies-literature
| S-EPMC5599779 | biostudies-literature
| S-EPMC3811179 | biostudies-literature
| S-EPMC5474679 | biostudies-literature
| S-EPMC3932655 | biostudies-other
| S-EPMC6045964 | biostudies-literature
| S-EPMC4250219 | biostudies-literature
| S-EPMC5466059 | biostudies-literature